ERBB2 and breast carcinoma: Another study found that the variety of molecular subtypes of breast carcinoma was associated with different survival rates and that the survival was the lowest among the HER-2 overexpressed and triple-negative groups, even after consecutive treatment (Kongsiang et al., 2015).